Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,241,009
  • Shares Outstanding, K 79,049
  • Annual Sales, $ 445,760 K
  • Annual Income, $ 24,140 K
  • EBIT $ 22 M
  • EBITDA $ 46 M
  • 60-Month Beta 1.88
  • Price/Sales 6.63
  • Price/Cash Flow 40.94
  • Price/Book 2.66

Options Overview Details

View History
  • Implied Volatility 50.30% (-4.91%)
  • Historical Volatility 34.76%
  • IV Percentile 7%
  • IV Rank 11.97%
  • IV High 109.12% on 04/14/25
  • IV Low 42.30% on 08/13/25
  • Expected Move (DTE 35) 1.36 (3.26%)
  • Put/Call Vol Ratio 82.25
  • Today's Volume 333
  • Volume Avg (30-Day) 189
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 2,244
  • Open Int (30-Day) 2,219
  • Expected Range 40.32 to 43.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.28
  • Low Estimate 0.26
  • Prior Year 0.24
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.33 +3.40%
on 01/16/26
46.76 -10.81%
on 01/07/26
-1.52 (-3.52%)
since 12/16/25
3-Month
34.38 +21.29%
on 10/22/25
50.71 -17.77%
on 11/25/25
+5.89 (+16.45%)
since 10/16/25
52-Week
22.61 +84.43%
on 07/18/25
50.71 -17.77%
on 11/25/25
+0.60 (+1.46%)
since 01/16/25

Most Recent Stories

More News
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Grew full-year revenue to between $515 million and $517 million, an increase of 16%

VCYT : 41.57 (+1.39%)
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at...

VCYT : 41.57 (+1.39%)
Veracyte to Participate in Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. ...

VCYT : 41.57 (+1.39%)
Veracyte: Q3 Earnings Snapshot

Veracyte: Q3 Earnings Snapshot

VCYT : 41.57 (+1.39%)
Veracyte Announces Third Quarter 2025 Financial Results

Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast...

VCYT : 41.57 (+1.39%)
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Landmark studies leverage Afirma GRID whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups

VCYT : 41.57 (+1.39%)
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November...

VCYT : 41.57 (+1.39%)
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025

VCYT : 41.57 (+1.39%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

USA News Group News Commentary

VCYT : 41.57 (+1.39%)
QURE : 22.84 (+3.91%)
HUM : 273.28 (-3.76%)
AVAI : 0.7401 (-4.75%)
EDIT : 2.03 (-2.87%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

/CNW/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...

VCYT : 41.57 (+1.39%)
HUM : 273.28 (-3.76%)
QURE : 22.84 (+3.91%)
AVAI : 0.7401 (-4.75%)
EDIT : 2.03 (-2.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 44.19
2nd Resistance Point 43.45
1st Resistance Point 42.22
Last Price 41.57
1st Support Level 40.25
2nd Support Level 39.51
3rd Support Level 38.28

See More

52-Week High 50.71
Last Price 41.57
Fibonacci 61.8% 39.98
Fibonacci 50% 36.66
Fibonacci 38.2% 33.34
52-Week Low 22.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar